Please assess the completion status of the following clinical trial:

Trial Title: EPAT: Estrogen in the Prevention of Atherosclerosis Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Postmenopausal female (serum estradiol less than 20 pg/ml)~* 46 to 80 years old~* Fasting LDL-C levels 130 to 210 mg/dL~* Triglyceride levels less than 400 mg/dL~* Current non-smoker~Exclusion Criteria:~* Clinical evidence of cardiovascular disease~* HDL-C level less than 30 mg/dL~* Fasting blood glucose greater than 200 mg/dL~* Previous hormonal replacement therapy (non-contraceptive) over 10 years duration and/or current use within 1 month~* Uncontrolled hypertension~* Untreated thyroid disease~* Renal insufficiency~* Clinical evidence of congestive heart failure~* Life threatening disease with prognosis less than 5 years~* Alcohol intake greater than 5 drinks per day (1 drink = 1 1/2 oz distilled spirits, 4 oz wine, or 12 oz beer) or substance abuse (intravenous drug abuse, cocaine use)~* History of estrogen dependent cancer or detected at screening or any other disorder precluding use of ERT~* Hot flashes greater than 5 per day which interfere with daily activity and preclude randomization to placebo.

- Gender: FEMALE
- Minimum Age: 46 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Based on this trial design, predict the completion outcome and termination type (if applicable).